Stock data
Cadrenal Therapeutics, Inc. (CVKD)
Cadrenal Therapeutics, Inc. (CVKD) reported net income of -US$13.24M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$13.46M | -US$13.24M | — |
| 2024 | — | — | -US$10.96M | -US$10.65M | — |
| 2023 | — | — | -US$7.63M | -US$8.36M | — |
| 2022 | — | — | -US$2.70M | -US$6.71M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$3.32M | — |
| 2026-03-31 | — | -US$2.50M | — |
| 2025-12-31 | — | -US$3.04M | — |
| 2025-09-30 | — | -US$2.69M | — |
| 2025-06-30 | — | -US$3.67M | — |
| 2025-03-31 | — | -US$3.85M | — |
| 2024-12-31 | — | -US$4.19M | — |
| 2024-09-30 | — | -US$2.41M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.